| Literature DB >> 35836613 |
M C Stumpfe1, R E Horch1, A Arkudas1, A Cai1, W Müller-Seubert1, T Hauck1, I Ludolph1.
Abstract
Background: Hidradenitis suppurativa is manifested by painful abscesses and scarring of sweat glands. Axillary, inguinal and genital regions are mostly affected. Multiple options exist in the treatment of hidradenitis suppurativa. The aim of this retrospective, mono-center cohort study was to analyze the outcome of different treatment methods after radical excision of hidradenitis suppurativa.Entities:
Keywords: acne inversa; bacterial burden; flap surgery; hidradenitis suppurativa; negative-pressure wound therapy
Year: 2022 PMID: 35836613 PMCID: PMC9273893 DOI: 10.3389/fsurg.2022.867487
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
The Hurley classification of hidradenitis suppurativa.
| Stage 1 | Single or multiple abscess formation without sinus tracts and cicatrization |
| Stage 2 | Recurrent single or multiple abscesses, widely separated, with limited sinus tracts and cicatrization |
| Stage 3 | Diffuse or near-diffuse involvement of multiple interconnected tracts and abscesses across an entire area |
Figure 1Flow chart with included patient numbers and reasons for exclusion and illustration of the subgroups primary vs. secondary reconstruction and reconstructive technique; SIH, secondary intention healing; SIHCS, secondary intention healing with buried chip skin grafts; STSG, split-thickness skin graft; FCF, fasciocutaneous flaps.
Overview of the quantity of bacteria and semi-quantitative description of bacteria.
| Quantity of bacteria under culture | Semi-quantitative description |
|---|---|
| After enrichment | 0.5 |
| Sparse (+) | 1.0 |
| Moderate (++) | 2.0 |
| Several (+++) | 3.0 |
| Plenty (++++) | 4.0 |
Demographic data, risk factors and localization of the primary and secondary treated patients.
| Characteristic | Primary ( | Secondary ( |
|---|---|---|
| Female gender | 36% (8/22) | 22% (5/22) |
| Mean age in years (SD) | 34.0 ± 10.9 | 39.7 ± 12.8 |
| Disease duration in years | 8.7 (0.1–40.7) | 13.3 (0.2–40.7) |
| Mean length (range min – max) of hospital stay in days | 11.5 (4.0–24.0) | 18.7 (7.0–36.0) |
| Risk factors | ||
| Smoking | 41% (9/22) | 18% (4/22) |
| Obesity | 5% (1/22) | 36% (8/22) |
| Diabetes mellitus 2 | 0% (0/22) | 9% (2/22) |
| Localization | ||
| Axilla right | 4 | 3 |
| Axilla left | 3 | 7 |
| Inguinal right | 5 | 4 |
| Inguinal left | 4 | 4 |
| Anogenital | 4 | 3 |
| mons pubis | 2 | 1 |
| Median duration (range min – max) between debridement and reconstruction in days | n/a | 20.3 (3.0–56.0) |
Until intervention; primary, primary reconstruction; secondary, secondary reconstruction; n, number of localizations.
Overview of the reconstruction techniques distributed among the localizations; Categorical data are expressed as % (n/N).
| Characteristic | SIH ( | SIHCS ( | STSG ( | FCF ( |
|---|---|---|---|---|
| Female gender | 14% (1/7) | 0% (0/10) | 46% (7/15) | 42% (5/12) |
| Mean age | 31.2 ± 11.4 | 47.0 ± 5.6 | 33.7 ± 13.8 | 37.4 ± 8.9 |
| Disease duration in years | 11.5 (4.3–40.7) | 18.7 (4.1–28.5) | 13.7 (1.9–40.7) | 8.8 (0.8–20.3) |
| Mean length (range min – max) of hospital stay in days | 10.1 (5.0–15.0) | 19.6 (7.0–36.0) | 16.2 (6.0–32.0) | 13.8 (4.0–29.0) |
| Risk factors | ||||
| Smoking | 43% (3/7) | 40% (4/10) | 13% (2/15) | 33% (4/12) |
| Obesity | 14% (1/7) | 0% (0/10) | 46% (7/15) | 8% (1/12) |
| Diabetes mellitus 2 | 0% (0/4) | 0% (0/10) | 7% (1/15) | 8% (1/12) |
| Localization | ||||
| Axilla right | 1 | 0 | 4 | 2 |
| Axilla left | 0 | 0 | 7 | 3 |
| Inguinal right | 2 | 3 | 2 | 2 |
| Inguinal left | 1 | 3 | 2 | 2 |
| Anogenital | 2 | 4 | 0 | 1 |
| Mons pubis | 1 | 0 | 0 | 2 |
| Mean duration between debridement and reconstruction in days | n/a | 34.0 (13.0–56.0) | 14.7 (3.0–27.0) | 11.8 (6.0–21.0) |
| No-NPWT/NPWT/NPWTi-d | 7/0/0 | 7/3/0 | 7/4/4 | 8/2/2 |
Continuous data are expressed as mean ± SD.
SIH, secondary intention healing; SIHCS, secondary intention healing with buried chip skin grafts; STSG, split-thickness skin graft; FCF , fasciocutaneous flaps, no-NPWT, no negative-pressure wound therapy, NPWT, negative-pressure wound therapy; NPWTi-d, negative-pressure wound therapy with instillation and dwell time.
Until intervention.
Figure 2Graphical representation of the time until recurrence in months between reconstruction and recurrence (mean); SIH, secondary intention healing; SIHCS, secondary intention healing with buried chip skin grafts; STSG, split-thickness skin graft; FCF, fasciocutaneous flaps; PR, primary reconstruction; SR, secondary reconstruction.
Detailed evaluation of the recurrence rate and time until recurrence in months between reconstruction and recurrence (mean).
| Characteristic | SIH ( | SIHCS ( | STSG ( | FCF ( |
|---|---|---|---|---|
| Recurrences | 29% (2/7) | 60% (6/10) | 26% (4/15) | 33% (4/12) |
| Mean duration (range) between reconstruction and recurrence in months | 35.0 (3.0–67.0) | 18.1 (1.0–40.0) | 60.0 (5.0–84.0) | 17.3 (8.0–31.0) |
SIH, secondary intention healing; SIHCS, secondary intention healing with buried chip skin grafts; STSG, split-thickness skin graft; FCF, fasciocutaneous flaps.
Summary of the wound swabs results; bacterial load (AB) and flora (NDB) before debridement (1. NDB/ 1. AB) and immediately before reconstruction (2. NDB; 2. AB).
| no NPWT | NPWT | NPWTi-d | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. NDB | 2. NDB | 1. AB | 2. AB | 1. NDB | 2. NDB | 1. AB | 2. AB | 1. NDB | 2. NDB | 1. AB | 2. AB | |
| Mean | 1.8 | 0.8 | 3.5 | 0.9 | 2.4 | 0.3 | 4.3 | 0.3 | 1.7 | 1.4 | 3.0 | 3.2 |
| Minimum | 1.0 | 0.0 | 2.0 | 0.0 | 1.0 | 0.0 | 2.0 | 0.0 | 1.0 | 0.0 | 0.5 | 0.0 |
| Maximum | 2.0 | 1.0 | 5.0 | 2.0 | 4.0 | 1.0 | 7.5 | 1.0 | 3.0 | 2.0 | 6.0 | 6.0 |
| SD | 0.5 | 0.5 | 1.3 | 0.85 | 1.1 | 0.6 | 2.1 | 0.6 | 0.8 | 0.9 | 1.9 | 2.4 |
NPWT, negative pressure wound therapy; NPWTi-d, negative-pressure wound therapy with instillation and dwell time.
Figure 3Development of the bacterial flora (NDB) and load (AB) (before debridement (1. NDB/1. AB) and before reconstruction (2. NDB/2.AB); NPWT, negative pressure wound therapy; NPWTi-d, negative-pressure wound therapy with instillation and dwell time.